Description
Watch VENN session 2 “Initiation”.
Here our faculty discuss the initiation of vosoritide therapy in individuals with achondroplasia, with observations from both a doctor’s and a nurse’s perspective. In this session from the V.E.NN virtual meeting, they will talk about what is required from a site readiness perspective, review the baseline measurements and investigations that should be performed, and examine the training needs for patients and their families. The session also includes a case study discussing treatment initiation, as well as two Q&As, where our expert faculty respond to audience questions about starting vosoritide therapy.
The total viewing time for this session is 1 hour 36 minutes. To view individual talks from within the Initiation session, please refer to the following timings:
• Overview, agenda and disclosures – 00:00:00 to 00:03:31
• Site readiness: centre infrastructure and capability for effective management (Tilman Rohrer) – 00:03:32 to 00:23:36
• Baseline measurements and investigations (Tilman Rohrer) – 00:23:37 to 00:40:12
• Training for patients and families (Kerstin Schütz) – 00:40:13 to 00:54:34
• Q&A – 00:54:35 to 01:15:40
• Case study: Initiation (Tilman Rohrer) – 01:15:41 to 01:31:14
• Case study discussion/Q&A – 01:31:15 to 01:35:05
• Closing remarks – 01:35:06 to 1:36:07
This video is for viewing by healthcare professionals only.
VOXZOGO®▼ (vosoritide) is indicated for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing. If you would like to view the current abbreviated prescribing information, please visit https://www.achondroplasia.expert/prescribing-information.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported to drugsafety@bmrn.com.
For general questions about BioMarin disease areas or products, contact medinfoeu@bmrn.com.
Date of preparation: November 2022; EU-VOX-00740